Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $100.00

Ionis Pharmaceuticals (NASDAQ:IONS) had its price target boosted by Piper Sandler from $87.00 to $100.00 in a report released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Other analysts have also recently issued reports about the stock. Morgan Stanley set a $95.00 price target on shares of Ionis Pharmaceuticals and gave the company an “overweight” rating in a research note on Wednesday. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $73.00 to $77.00 and gave the company a “hold” rating in a research report on Thursday. Leerink Partners boosted their target price on Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Wall Street Zen lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, HC Wainwright raised their price target on Ionis Pharmaceuticals from $100.00 to $110.00 and gave the company a “buy” rating in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.80.

Ionis Pharmaceuticals Stock Up 0.7%

Shares of IONS opened at $81.15 on Friday. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.81 and a current ratio of 3.83. The company has a 50-day simple moving average of $81.33 and a 200-day simple moving average of $72.32. Ionis Pharmaceuticals has a 52 week low of $23.95 and a 52 week high of $86.74. The firm has a market capitalization of $13.41 billion, a P/E ratio of -33.26 and a beta of 0.31.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). Ionis Pharmaceuticals had a negative net margin of 40.36% and a negative return on equity of 68.82%. The business had revenue of $203.00 million during the quarter, compared to the consensus estimate of $156.07 million. During the same period in the prior year, the firm earned ($0.66) earnings per share. The business’s quarterly revenue was down 10.6% compared to the same quarter last year. On average, equities research analysts expect that Ionis Pharmaceuticals will post -3.5 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Eugene Schneider sold 6,179 shares of the company’s stock in a transaction dated Friday, January 30th. The stock was sold at an average price of $83.45, for a total value of $515,637.55. Following the completion of the sale, the executive vice president directly owned 69,702 shares of the company’s stock, valued at $5,816,631.90. This represents a 8.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Brett P. Monia sold 29,430 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $85.79, for a total transaction of $2,524,799.70. Following the transaction, the chief executive officer directly owned 254,497 shares in the company, valued at $21,833,297.63. The trade was a 10.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 436,579 shares of company stock valued at $35,367,233 in the last ninety days. 2.71% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently bought and sold shares of IONS. Capital World Investors grew its holdings in shares of Ionis Pharmaceuticals by 41.2% in the 4th quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock valued at $1,420,918,000 after buying an additional 5,238,571 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Ionis Pharmaceuticals by 253.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock worth $150,138,000 after acquiring an additional 2,724,400 shares in the last quarter. Franklin Resources Inc. grew its stake in Ionis Pharmaceuticals by 19,941.6% in the fourth quarter. Franklin Resources Inc. now owns 1,321,345 shares of the company’s stock valued at $104,532,000 after acquiring an additional 1,314,752 shares during the period. Baker BROS. Advisors LP increased its holdings in shares of Ionis Pharmaceuticals by 216.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,791,841 shares of the company’s stock worth $141,753,000 after acquiring an additional 1,225,043 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Ionis Pharmaceuticals by 7,219.3% during the third quarter. Marshall Wace LLP now owns 958,829 shares of the company’s stock worth $62,727,000 after purchasing an additional 945,729 shares during the period. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Piper Sandler raised its price target to $100 and moved to an “overweight” rating, signaling ~23% upside from current levels — a clear buy-side endorsement. Article Title
• Positive Sentiment: Needham lifted its price target to $103 from $90, another analyst upgrade supporting the rally and reflecting greater confidence in revenue trajectory. Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
• Positive Sentiment: Updates to Tryngolza outlook are materially positive: recent analysis lifts peak revenue estimates (several sources cite >$2B for Tryngolza and company-level peak revenue/royalty/milestone potential in the multi‑billion range), and management guides to cash-flow breakeven by 2028 — bullish for long-term value. Ionis Pharmaceuticals: Digesting Recent Events
• Neutral Sentiment: Company presented at Oppenheimer’s healthcare conference; slides/transcript provide additional visibility into pipeline progress and commercialization strategy but are informational rather than catalytic. IONS Presents at Oppenheimer Conference Transcript
• Neutral Sentiment: General earnings call coverage/recaps are available for detail on management commentary and guidance; useful for modeling but not single-handedly market-moving. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results were mixed: revenue and Tryngolza sales beat expectations, but EPS missed estimates and management gave a softer 2026 outlook, which pressured the stock in after-hours/early trade. Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
• Negative Sentiment: Coverage noted the EPS miss led to a gap-down reaction in some sessions; near-term uptake for new drugs and the FY2026 revenue cadence remain the main risk factors to watch. Shares Gap Down on Disappointing Earnings
• Negative Sentiment: Stifel raised its target modestly to $77 but kept a “hold” rating — the lower relative PT signals at least one shop sees limited near-term upside. Article Title

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.